Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients

  • Author: José R. Arribas, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 10/12/18 (What's New)

Summary

  • Boosted PI monotherapy for maintenance of virologic suppression is an investigational therapeutic strategy that takes advantage of the very high genetic barrier to resistance of boosted PIs 
    • Lopinavir/Ritonavir Monotherapy
    • Only 10% of virologically suppressed patients receiving lopinavir/ritonavir plus 2 NRTIs switched to lopinavir/ritonavir monotherapy experienced viral rebound if they had been virologically suppressed for ≥ 6 months before switching[Bierman 2009]
      • Patients experiencing virologic rebound were able to reattain virologic suppression with the reintroduction of NRTIs[Bierman 2009; Mathis 2011]
    Atazanavir/Ritonavir Monotherapy
      Darunavir/Ritonavir Monotherapy

      Action required

      Keywords: Switch Strategies

      ©2018 Clinical Care Options, LLC. All Rights Reserved.

      The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.